Journal Article

DZNE-2021-00740

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Efficacy of naltrexone in borderline personality disorder, a retrospective analysis in inpatients.

Timäus, C. (Corresponding author) ; Meiser, M. ; Wiltfang, J.DZNE* ; Bandelow, B. ; Wedekind, D.

2021
Wiley New York, NY [u.a.]

This record in other databases:    

Please use a persistent id in citations: doi:10.1002/hup.2800

Abstract: The endogenous opioid system is assumed to be involved in the pathophysiology of borderline personality disorder (BPD), and opioid antagonists may improve core features of BPD. The aim of this retrospective chart analysis was to evaluate the relative contribution of the opioid antagonist naltrexone and other psychotropic drugs in the improvement of overall symptomatology in BPD.One hundred sixty-one inpatients with BPD treated between January 2010 and October 2013 were classified as either treatment responders or non-responders. Treatment responders were defined as subjects with significant improvements in four or more symptoms from a defined symptom list. The relative contribution of all psychotropic drugs to improvement of BPD symptomatology was assessed by means of a stepwise logistic regression.None of the drugs applied contributed significantly to improvement, with the exception of naltrexone (odds ratio [OR] 43.2, p ≤ 0.0001). Patients treated with naltrexone (N = 55, 34%) recovered significantly more often. Higher doses of naltrexone were more effective (OR 791.8, p ≤ 0.0001) than lower doses (OR 26.6, p ≤ 0.0001); however, even low-dose treatment was better than any other pharmacological treatment.Naltrexone was associated with improvement in BPD in a dose-dependent manner. The present study provides additional evidence that dysregulation of the endogenous opioid system is implicated in the pathophysiology of BPD symptoms.

Keyword(s): Borderline Personality Disorder: diagnosis (MeSH) ; Borderline Personality Disorder: drug therapy (MeSH) ; Humans (MeSH) ; Inpatients (MeSH) ; Naltrexone: therapeutic use (MeSH) ; Narcotic Antagonists: therapeutic use (MeSH) ; Retrospective Studies (MeSH) ; borderline personality disorder ; naltrexone ; neuropeptide ; opioid receptor ; psychopharmacology

---

Contributing Institute(s):

1. Alzheimer Biomarker and Clinical Study Group (AG Wiltfang)

Research Program(s):

1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

Appears in the scientific report 2021

---

Database coverage:
; ; ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; DEAL Wiley ; Ebsco Academic Search ; Essential Science Indicators ; IF < 5 ; JCR ; Nationallizenz ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---